Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.

Insmed Incorporated

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

BRIDGEWATER, N.J., SEPT. 4, 2026 /PRNEWSWIRE/ -- INSMED INCORPORATED (NASDAQ: INSM), A PEOPLE-FIRST GLOBAL BIOPHARMACEUTICAL COMPANY STRIVING TO DELIVER FIRST- AND BEST-IN-CLASS THERAPIES TO TRANSFORM THE LIVES OF PATIENTS FACING SERIOUS DISEASES, TODAY ANNOUNCED THE GRANTING OF INDUCEMENT AWARDS TO 128 NEW EMPLOYEES.

INSMED REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

 NEW DATA EXPLORE EFFICACY AND SAFETY OF BRINSUPRI  (BRENSOCATIB) IN PATIENTS WITH NON-CYSTIC FIBROSIS BRONCHIECTASIS (NCFB) AND HISTORY OF NONTUBERCULOUS MYCOBACTERIAL (NTM) LUNG DISEASE NEW RESEARCH EXAMINES TREPROSTINIL PALMITIL INHALATION POWDER (TPIP) VIA COMPERA 2.0 RISK ASSESSMENT IN PULMONARY ARTERIAL HYPERTENSION (PAH) BRIDGEWATER, N.J., SEPT. 3, 2026 /PRNEWSWIRE/ -- INSMED INCORPORATED (NASDAQ: INSM), A PEOPLE-FIRST GLOBAL BIOPHARMACEUTICAL COMPANY STRIVING TO DELIVER FIRST- AND BEST-IN-CLASS THERAPIES TO TRANSFORM THE LIVES OF PATIENTS FACING SERIOUS DISEASES, TODAY ANNOUNCED THAT FIVE ABSTRACTS HIGHLIGHTING DATA FROM ITS RESPIRATORY PORTFOLIO HAVE BEEN ACCEPTED FOR PRESENTATION AT THE EUROPEAN RESPIRATORY SOCIETY (ERS) CONGRESS 2026 TAKING PLACE SEPT.

INSMED TO PRESENT DATA ACROSS ITS RESPIRATORY PORTFOLIO, INCLUDING NEW LATE-BREAKING ARIKAYCE (AMIKACIN LIPOSOME INHALATION SUSPENSION) RESULTS FROM PHASE 3B ENCORE STUDY AT THE EUROPEAN RESPIRATORY SOCIETY CONGRESS 2026

BRIDGEWATER, N.J., AUG. 26, 2026 /PRNEWSWIRE/ -- INSMED INCORPORATED (NASDAQ: INSM), A PEOPLE-FIRST GLOBAL BIOPHARMACEUTICAL COMPANY STRIVING TO DELIVER FIRST- AND BEST-IN-CLASS THERAPIES TO TRANSFORM THE LIVES OF PATIENTS FACING SERIOUS DISEASES, TODAY ANNOUNCED THAT MANAGEMENT WILL PRESENT AT THE FOLLOWING INVESTOR CONFERENCES: 12TH ANNUAL CANTOR FITZGERALD GLOBAL HEALTHCARE CONFERENCE IN NEW YORK CITY ON WEDNESDAY, SEPTEMBER 9, 2026, AT 8:00 A.M.

INSMED TO PRESENT AT SEPTEMBER 2026 INVESTOR CONFERENCES

 FIRST-IN-DISEASE AND FIRST-IN-CLASS THERAPY APPROVED IN JAPAN FOR PATIENTS WITH NON-CYSTIC FIBROSIS BRONCHIECTASIS (NCFB), A PROGRESSIVE DISEASE THAT CAN LEAD TO PERMANENT LUNG DAMAGE  BRIDGEWATER, N.J., AUG. 24, 2026 /PRNEWSWIRE/ -- INSMED INCORPORATED (NASDAQ: INSM), A PEOPLE-FIRST GLOBAL BIOPHARMACEUTICAL COMPANY STRIVING TO DELIVER FIRST- AND BEST-IN-CLASS THERAPIES TO TRANSFORM THE LIVES OF PATIENTS FACING SERIOUS DISEASES, TODAY ANNOUNCED THAT JAPAN'S MINISTRY OF HEALTH, LABOUR AND WELFARE (MHLW) HAS APPROVED BRINSUPRI  (BRENSOCATIB 25-MG TABLET), AN ORAL, ONCE-DAILY TREATMENT FOR NON-CYSTIC FIBROSIS BRONCHIECTASIS (NCFB) IN ADULTS AND PEDIATRIC PATIENTS 12 YEARS AND OLDER.

BRINSUPRI (BRENSOCATIB) APPROVED BY JAPAN'S MINISTRY OF HEALTH, LABOUR AND WELFARE FOR THE TREATMENT OF PATIENTS WITH NON-CYSTIC FIBROSIS BRONCHIECTASIS, A SERIOUS, CHRONIC LUNG DISEASE

TOTAL COMPANY REVENUES OF $425.5 MILLION FOR THE SECOND QUARTER OF 2026 BRINSUPRI  (BRENSOCATIB) REVENUES OF $309.2 MILLION FOR THE SECOND QUARTER OF 2026, REFLECTING 49% GROWTH OVER THE FIRST QUARTER OF 2026 ARIKAYCE  (AMIKACIN LIPOSOME INHALATION SUSPENSION) REVENUES OF $116.3 MILLION FOR THE SECOND QUARTER OF 2026, REFLECTING 8% GROWTH OVER THE SECOND QUARTER OF 2025 COMPANY RAISES 2026 BRINSUPRI REVENUE GUIDANCE TO $1.25 BILLION TO $1.40 BILLION COMPANY REITERATES 2026 ARIKAYCE REVENUE GUIDANCE OF $450 MILLION TO $470 MILLION COMPANY RAISES PEAK REVENUE ESTIMATE FOR ITS THREE LEAD PROGRAMS TO MORE THAN $14 BILLION TOTAL PEAK REVENUE ESTIMATE CONSISTS OF MORE THAN $7 BILLION FOR BRINSUPRI, MORE THAN $6 BILLION FOR TPIP, AND MORE THAN $1 BILLION FOR ARIKAYCE BRIDGEWATER, N.J., AUG. 6, 2026 /PRNEWSWIRE/ -- INSMED INCORPORATED (NASDAQ: INSM), A PEOPLE-FIRST GLOBAL BIOPHARMACEUTICAL COMPANY STRIVING TO DELIVER FIRST- AND BEST-IN-CLASS THERAPIES TO TRANSFORM THE LIVES OF PATIENTS FACING SERIOUS DISEASES, TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2026, AND PROVIDED A BUSINESS UPDATE.

INSMED REPORTS SECOND-QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BRIDGEWATER, N.J., JULY 23, 2026 /PRNEWSWIRE/ -- INSMED INCORPORATED (NASDAQ: INSM), A PEOPLE-FIRST GLOBAL BIOPHARMACEUTICAL COMPANY STRIVING TO DELIVER FIRST- AND BEST-IN-CLASS THERAPIES TO TRANSFORM THE LIVES OF PATIENTS FACING SERIOUS DISEASES, TODAY ANNOUNCED THAT IT WILL RELEASE ITS SECOND-QUARTER 2026 FINANCIAL RESULTS ONTHURSDAY, AUGUST 6, 2026.

INSMED TO HOST SECOND-QUARTER 2026 FINANCIAL RESULTS CONFERENCE CALL ON THURSDAY, AUGUST 6, 2026

 12-MONTH DATA DEMONSTRATED SUSTAINED IMPROVEMENT WITH TPIP ACROSS ALL SECONDARY EFFICACY MEASURES INCLUDING REDUCTION IN MORTALITY RISK STATUS BY REVEAL LITE 2.0 PLACEBO CROSSED GROUP DEMONSTRATED TREATMENT RESPONSE ON TPIP, ACHIEVING SIMILAR OUTCOMES TO THE TPIP CONTINUED GROUP BY MONTH 12 TPIP WAS SAFE AND WELL-TOLERATED WITH NO NEWLY IDENTIFIED SAFETY SIGNALS THROUGH MONTH 12; DOSES UP TO 1,280 G ONCE DAILY WERE PERMITTED IN THE OLE STUDY  THESE OLE DATA, COMBINED WITH ONCE-DAILY INHALED ADMINISTRATION, REINFORCE TPIP'S POTENTIAL TO BECOME THE PROSTANOID OF CHOICE FOR PATIENTS WITH PAH   INSMED TO HOST INVESTOR CALL THURSDAY, JULY 16, 2026,AT 8:00 A.M. ET  BRIDGEWATER, N.J.

INSMED ANNOUNCES POSITIVE 12-MONTH DATA FROM THE ONGOING OPEN-LABEL EXTENSION STUDY OF TREPROSTINIL PALMITIL INHALATION POWDER (TPIP) IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION

HANNOVER, GERMANY, JUNE 25, 2026 (GLOBE NEWSWIRE) -- EMBARC ANNOUNCES ITS INTENTION TO COLLABORATE WITH INSMED ON LANDMARK INTERVENTIONAL STUDY EVALUATING DISEASE MODIFICATION POTENTIAL OF BRENSOCATIB IN BRONCHIECTASIS LONG-TERM, OPEN-LABEL STUDY TO ENROLL APPROXIMATELY 3,000 PATIENTS ACROSS EUROPE

EMBARC ANNOUNCES ITS INTENTION TO COLLABORATE WITH INSMED ON LANDMARK INTERVENTIONAL STUDY EVALUATING DISEASE MODIFICATION POTENTIAL OF BRENSOCATIB IN BRONCHIECTASIS

BRIDGEWATER, N.J., JUNE 23, 2026 /PRNEWSWIRE/ -- INSMED INCORPORATED (NASDAQ: INSM), A PEOPLE-FIRST GLOBAL BIOPHARMACEUTICAL COMPANY STRIVING TO DELIVER FIRST- AND BEST-IN-CLASS THERAPIES TO TRANSFORM THE LIVES OF PATIENTS FACING SERIOUS DISEASES, TODAY ANNOUNCED THE APPOINTMENT OF SAMUELE BUTERA AS SENIOR VICE PRESIDENT, GENERAL MANAGER, GLOBAL RESPIRATORY, EFFECTIVE TODAY.

INSMED APPOINTS SAMUELE BUTERA AS SENIOR VICE PRESIDENT, GENERAL MANAGER, GLOBAL RESPIRATORY

BRIDGEWATER, N.J., JUNE 4, 2026 /PRNEWSWIRE/ -- INSMED INCORPORATED (NASDAQ: INSM), A PEOPLE-FIRST GLOBAL BIOPHARMACEUTICAL COMPANY STRIVING TO DELIVER FIRST- AND BEST-IN-CLASS THERAPIES TO TRANSFORM THE LIVES OF PATIENTS FACING SERIOUS DISEASES, TODAY ANNOUNCED THE GRANTING OF INDUCEMENT AWARDS TO 103 NEW EMPLOYEES.

Insmed Incorporated

INSM

Price

Financial Reports

No items found.

Press Releases

Insmed Incorporated

INSM.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

INSM